Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks.

Scott K Fung Calvin Qian PanGrace Lai-Hung WongWai Kay Seto Sang Hoon AhnChi-Yi ChenHie-Won L HannMaciej S JablkowskiYun Joon KimCihan YurdaydinCheng-Yuan PengTuan NguyenHiroshi YatsuhashiJohn F FlahertyLeland J YeeFrida AbramovHongyuan WangDzhamal AbdurakhmanovYoung Suk Lim Maria Buti Ferret

Published in: Alimentary pharmacology & therapeutics (2023)

Despite on-treatment differences in lipid profiles with TAF and TDF, predicted cardiovascular risk and clinical events were similar for both groups after 96 weeks.

Keyphrases

cardiovascular disease
antiretroviral therapy
hepatitis b virus
gestational age
type diabetes
fatty acid
cardiovascular risk factors
metabolic syndrome
liver fibrosis